|Videos|April 6, 2023

Clinical Assessment of Key Subgroups of the Phase 3 Maia Study in Transplant-Ineligible Patients with NDMM

Author(s)Shaji Kumar, MD, Mayo Clinic, Sandy Wong, MD, Alexander Lesokhin, MD

Dr Sandy Wong reviews data from a patient subgroup analysis of the MAIA trial in transplant-ineligible NDMM.

Episodes in this series

EP. 1 GRIFFIN Trial in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Final Subgroup Analysis

EP. 1 GRIFFIN Trial in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Final Subgroup Analysis

EP. 2 Treatment Approaches in Transplant-Eligible NDMM

EP. 2 Treatment Approaches in Transplant-Eligible NDMM

EP. 3 Upfront Stem Cell Transplant and Maintenance Therapy in Transplant-Eligible NDMM

EP. 3 Upfront Stem Cell Transplant and Maintenance Therapy in Transplant-Eligible NDMM

EP. 4 Analysis of Patients with Transplant-Eligible NDMM with High-Risk Cytogenetic Abnormalities who Received Frontline Daratumumab-Based Quadruplet Therapy

EP. 4 Analysis of Patients with Transplant-Eligible NDMM with High-Risk Cytogenetic Abnormalities who Received Frontline Daratumumab-Based Quadruplet Therapy

EP. 5 Treatment Approaches in High-Risk Transplant-Eligible NDMM Based on MRD Negativity

EP. 5 Treatment Approaches in High-Risk Transplant-Eligible NDMM Based on MRD Negativity

EP. 6 Planned Interim Analysis of the GMMG-Concept Trial in High-Risk NDMM

EP. 6 Planned Interim Analysis of the GMMG-Concept Trial in High-Risk NDMM

EP. 7 Comparing Quadruplet Combination Treatment Regimens in NDMM

EP. 7 Comparing Quadruplet Combination Treatment Regimens in NDMM

EP. 8 Updated Analysis of the Phase 3 MAIA Study in Transplant-Ineligible Patients with NDMM

EP. 8 Updated Analysis of the Phase 3 MAIA Study in Transplant-Ineligible Patients with NDMM

EP. 9 Clinical Assessment of Key Subgroups of the Phase 3 Maia Study in Transplant-Ineligible Patients with NDMM

EP. 9 Clinical Assessment of Key Subgroups of the Phase 3 Maia Study in Transplant-Ineligible Patients with NDMM

EP. 10 IFM2020-05/Benefit: Isatuximab Plus Lenalidomide, Dexamethasone, and Bortezomib for Elderly Patients with Transplant-Ineligible NDMM

EP. 10 IFM2020-05/Benefit: Isatuximab Plus Lenalidomide, Dexamethasone, and Bortezomib for Elderly Patients with Transplant-Ineligible NDMM

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.

October 29th, 2026

Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?

“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.

$FDA Receives BLA for Etentamig in Relapsed/Refractory Multiple Myeloma$

October 27th, 2026

FDA Receives BLA for Etentamig in Relapsed/Refractory Multiple Myeloma

Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.

The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.

October 27th, 2026

Elranatamab Improves PFS vs Standard Regimens in R/R Multiple Myeloma

The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.

Trending on CancerNetwork

AI-Measured Tumor Volume on PSMA PET-CT Linked With Survival in Prostate Cancer

How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?

Sac-TMT Earns FDA Priority Review in Pretreated Endometrial Cancer

Expanding Access to Advanced Radiation Services Across a Network

Mapping Practical Steps to Expand CAR T-Cell Access in Multiple Myeloma